Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

Abiomed Hits New 52-Week High: 4 Factors Driving the Stock

10h zacks
Abiomed, Inc. (ABMD - Free Report) scaled a new 52-week high of $268.72 on Feb 16, eventually closing a bit lower at $267.74. The company’s shares have gained 74.6% in the last six months, compared with the broader industry’s 14.6% gain. (59-0)

Abiomed's Extended FDA Nod for Impella Refines PCI Diagnosis

2018-02-16 zacks
Abiomed, Inc. (ABMD - Free Report) recently announced that its flagship Impella 2.5 and Impella CP heart-pumps have received Pre-Market Approval (PMA) from the FDA for expanded use. With this, the products will now be used during elective and urgent high-risk percutaneous coronary intervention (PCI) procedures. (46-0)

Your Daily Pharma Scoop: Achaogen Update, Catabasis' Positive Results, Bristol-Myers Squibb/Nektar Collaboration

2018-02-15 seekingalpha
Today we will focus on Achaogen (AKAO), which got a slight boost after Tetraphase Pharma’s (TTPH) drug failed to beat ertapenem in a late-stage cUTI study. (426-3)

Abiomed's Extended FDA Nod for Impella Boosts Women Health

2018-02-14 zacks
Abiomed, Inc. (ABMD - Free Report) recently announced expanded FDA Pre-Market Approval (PMA) for its flagship Impella 2.5, Impella CP, Impella 5.0 and Impella LD heart pumps. With this expanded PMA, these heart pumps can now be used to treat heart failure associated with cardiomyopathy leading to cardiogenic shock, including peripartum and postpartum cardiomyopathy (PPCM). (74-0)

BRIEF-Abiomed Receives Approval For Expanded FDA Indication For Cardiomyopathy With Cardiogenic Shock

2018-02-13 reuters

Quest Diagnostics Banks on Alliances, Long-Term View Solid

2018-02-08 zacks
On Feb 6, we issued an updated research report on Quest Diagnostics, Inc. (DGX - Free Report) , a major commercial laboratory services provider. The stock carries a Zacks Rank #2 (Buy). (59-0)

Millipede to Aid Boston Scientific, LOTUS Relaunch Lag Ails

2018-02-07 zacks
On Feb 4, 2018, we issued an updated research report on leading medical devices company, Boston Scientific Corporation (BSX - Free Report) . The stock carries a Zacks Rank #3 (Hold). (91-0)

Mazor Robotics Hits 52-Week High: What's Driving the Stock?

2018-02-05 zacks
On Feb 2, 2018, shares of Mazor Robotics Ltd. (MZOR - Free Report) reached a new 52-week high of $69.37, closing the session a tad lower at $64.72. (65-1)

Thermo Fisher Grows on New Buyouts Amid Tough Competition

2018-02-05 zacks
On Feb 2, we issued an updated research report on  Thermo Fisher Scientific, Inc. (TMO - Free Report) , a leading scientific instrument maker. The stock has a Zacks Rank #3 (Hold). (62-1)

ABIOMED (ABMD) Beats Earnings and Revenue Estimates in Q3

2018-02-02 zacks
ABIOMED Inc. (ABMD - Free Report) reported third-quarter fiscal 2018 adjusted earnings of 70 cents per share, easily beating the Zacks Consensus Estimate of 50 cents. Moreover, adjusted earnings per share grew a whopping 105.9% on a year-over-year basis. (35-0)

Your Daily Pharma Scoop: Synergy Update, Vertex Results, Affimed Data

2018-02-02 seekingalpha
Today we will discuss the update from Synergy Pharmaceuticals (SGYP), which has ended some of the recent uncertainty. Having said that, the news has not really given a boost to SGYP shares. This is because the future dilution risk still remains. (435-0)

ABIOMED, Inc. 2018 Q3 - Results - Earnings Call Slides

2018-02-01 seekingalpha
The following slide deck was published by ABIOMED, Inc. in conjunction with their 2018 Q3 earnings call. (19-0)

Veeva Systems' Product Portfolio Strong, Competition Rife

2018-01-31 zacks
On Jan 30, we issued an updated research report on Veeva Systems (VEEV - Free Report) . Growing demand for cloud-based and vault applications and a diverse product portfolio are key positives. However, the company has been struggling against foreign exchange headwinds and intense competition in niche markets. (55-0)

ABMD / ABIOMED, Inc. - Stock Institutional Ownership and Shareholders -

ABIOMED, Inc. (NASDAQ:ABMD) has 327 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 40,606,964 shares. Largest shareholders include Primecap Management Co/ca/, BlackRock Inc., Vanguard Group Inc, Baillie Gifford & Co, Palo Alto Investors, LLC, Brown Capital Management Llc, State Street Corp, Renaissance Technologies LLC, Henderson Group Plc, and Essex Woodlands Health Ventures, Inc. (62-0)

Intuitive Surgical (ISRG) Beats on Q4 Earnings & Revenues

2018-01-26 zacks
Intuitive Surgical Inc (ISRG - Free Report) posted adjusted earnings of $2.54 per share in the fourth quarter of 2017, which beat the Zacks Consensus Estimate of $2.27 and improved 25.1% year over year. (37-0)

CUSIP: 003654100